Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | PRCP | P42785 | 6/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514422 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL2303831 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29381539 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29597389 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL574702 | 1.00 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL18066416 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Potassium SCHEMBL18066432 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL18066413 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5439604 | 0.98 | TSHR (1.00) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Potassium SCHEMBL18066428 | 0.98 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112442523-B | Method for preparing (R) -1,2,3, 4-tetrahydroisoquinoline-1-formic acid and derivatives thereof by enzymatic resolution | 浙江大学 | 2024-06-21 | — | — | CN | claimed |
| CN-112481344-B | Preparation method of (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivative thereof | 苏州同力生物医药有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114341362-B | Preparation method of (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivative thereof, and levopraziquantel | 苏州同力生物医药有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-114364658-A | Preparation method and composition of levo-praziquantel and chiral intermediate thereof | 苏州同力生物医药有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114341362-A | (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivatives thereof and preparation method of levo-praziquantel | 苏州同力生物医药有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-12612398-B2 | Preparation method for (R)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, derivatives thereof and levo-praziquantel | TONGLI BIOMEDICAL CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12480148-B2 | Method for preparing (s)-1,2,3,4-tetrahydroisoquinoline-1 carboxylic acid and derivatives thereof | TONGLI BIOMEDICAL CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| CN-112442523-B | Method for preparing (R) -1,2,3, 4-tetrahydroisoquinoline-1-formic acid and derivatives thereof by enzymatic resolution | 浙江大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-112442523-B | Method for preparing (R) -1,2,3, 4-tetrahydroisoquinoline-1-formic acid and derivatives thereof by enzymatic resolution | 浙江大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-112442523-B | Method for preparing (R) -1,2,3, 4-tetrahydroisoquinoline-1-formic acid and derivatives thereof by enzymatic resolution | 浙江大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-114341362-B | Preparation method of (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivative thereof, and levopraziquantel | 苏州同力生物医药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-114341362-B | Preparation method of (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivative thereof, and levopraziquantel | 苏州同力生物医药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-109971802-B | Method for preparing (S) -1,2,3, 4-tetrahydroisoquinoline-1-formic acid and derivatives thereof by enzymatic resolution | 苏州同力生物医药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230107679-A1 | Method For Preparing (S)-1,2,3,4-Tetrahydroisoquinoline-1 Carboxylic Acid and Derivatives Thereof | TONGLI BIOMEDICAL CO., LTD. (CN) | 2023-04-06 | — | — | US | disclosed |
| CN-109384778-B | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 赛克里翁治疗有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-110016020-B | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 赛克里翁治疗有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220227766-A1 | PREPARATION METHOD FOR (R)-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXYLIC ACID, DERIVATIVES THEREOF AND LEVO-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| CN-114364658-A | Preparation method and composition of levo-praziquantel and chiral intermediate thereof | 苏州同力生物医药有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114341362-A | (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivatives thereof and preparation method of levo-praziquantel | 苏州同力生物医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114341362-A | (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivatives thereof and preparation method of levo-praziquantel | 苏州同力生物医药有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12480148-B2 | Method for preparing (s)-1,2,3,4-tetrahydroisoquinoline-1 carboxylic acid and derivatives thereof | IMPDH1, HSD17B12, COASY | TSHR 3603/4885NPSR1 2703/4885PRCP 3645/4885 |
| US-12612398-B2 | Preparation method for (R)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid, derivatives thereof and levo-praziquantel | CES1, LIPA, LIPC | TSHR 1129/4885NPSR1 2305/4885PRCP 570/4885 |
| US-20230107679-A1 | Method For Preparing (S)-1,2,3,4-Tetrahydroisoquinoline-1 Carboxylic Acid and Derivatives Thereof | IMPDH1, COASY, ALDH18A1 | TSHR 3631/4885NPSR1 2648/4885PRCP 3555/4885 |
| US-20220227766-A1 | PREPARATION METHOD FOR (R)-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXYLIC ACID, DERIVATIVES THEREOF AND LEVO-PRAZIQUANTEL | CES1, LIPA, PON1 | TSHR 1679/4885NPSR1 2475/4885PRCP 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.